Safeheal SAS raised €35 million (US$39.72 million) in an oversubscribed series C financing round for its temporary ...

The appointment May 6 of Vinay Prasad as the head of the U.S. FDA’s Center for Biologics Evaluation and Research (CBER) “bodes poorly” for Sarepta Therapeutics Inc.’s development-stage pipeline, said ...

Aldeyra Therapeutics Inc. is making another run at U.S. FDA clearance for reproxalap in dry eye disease (DED) after nailing ...

Cellecta Inc. made remote diagnostics and decentralized clinical trials significantly easier with the launch of its Drivermap Exp assay. The microsampling kit provides a “molecular snapshot” of 19,000 ...

Less than a week after announcing it had a new CEO, privately held Creyon Bio Inc. began a licensing and research partnership ...

Actuate Therapeutics Inc. said its lead candidate, elraglusib, in pancreatic cancer demonstrated a substantial improvement in median overall survival compared to data from the same phase II study ...

Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. reported the discovery of SHR-3591, an orally bioavailable AR proteolysis targeting chimera (PROTAC) designed to treat prostate tumors.

Scientists at University of Connecticut and University of Iowa have described phosphonamidate prodrugs reported to be useful for the treatment of cancer.

Nuevocor Pte. Ltd. has closed a $45 million series B, enabling it to move lead gene therapy NVC-001 into the clinic in the treatment of an inherited form of cardiomyopathy.

Aiming to develop a systemic therapy for advanced refractory cancers, researchers have designed a novel oncolytic adenovirus that selectively targets and kills cancer cells expressing mesothelin.

Prostate cancer remains a significant health concern for men globally, and the search for effective and targeted therapies continues. In a recent study, researchers from Guizhou Medical University ...

U.S. FDA Commissioner Marty Makary is starting to fill the vacancies at the agency that’s seen its senior leadership ravaged by retirements and terminations. Makary’s first pick is Vinay Prasad as the ...